{"id":{"repo_id":"uiuc","oai_identifier":"oai:www.ideals.illinois.edu:2142/106356"},"canonical_url":"https://search.dev.ndltd.org/etd/uiuc/oai:www.ideals.illinois.edu:2142/106356","repository":{"repo_id":"uiuc","name":"University of Illinois - Urbana-Champaign","base_url":"https://www.ideals.illinois.edu/oai-pmh"},"display":{"title":"The biosynthesis and discovery of lanthipeptides","abstract":"Natural products and their derivatives have been significant resources for the development of therapeutic compounds. They attracted interests from both academia and industry because of their high structural diversity and potential applications. Lanthipeptides are one class of natural products that have provided antibiotics to the food industry and drug candidates for treating human diseases. Lanthipeptides are polypeptides enzymatically decorated with lanthionine rings and sometimes other post-translational modifications, which dramatically elevate their protease-resistances, improved their chemical stabilities, and increased their structural complexity. To add onto the structure knowledge and biosynthetic toolkits for lanthipeptides, I investigated the biosynthesis and discovery of lanthipeptides during my Ph.D training. Duramycin/cinnamycin-type of lanthipeptides interact tightly with phosphatidylethanolamine and several of their members displayed high potential to be drug candidates. Duramycin contains an activity-essential lysinoalanine ring which is installed by a previously unknown hypothetical protein, DurN. In Chapter 2, I described the mechanism of action studies on DurN. I reconstituted the in vitro activity of DurN. Together with Dr. Cogan, we obtained the co-crystal structures of DurN with its product or substrate analog. We demonstrated that DurN catalyzes the lysinoalanine formation through a unique substrate-assisted catalysis mechanism. Enlightened by the biosynthesis of lanthipeptide, I further designed and initiated a proof-of-concept lanthipeptide discovery project based on the predictions for the potential mode of action of natural products, which is described in Chapter 3. I hypothesized that if the gene encoding a small molecule-processing enzyme locates in the biosynthetic gene cluster of a natural product on the bacterial genome, this processing enzyme may function as the immunity protein to prevent producer viability loss during the production of the natural products, and the natural product may target the small molecule. Following this hypothesis, I identified multiple lanthipeptide biosynthesis gene cluster candidates, and selected kib cluster from Kibdelsporangium phytohabitant KLBMP 1111T for verification. The lanthipeptide was produced in heterologous expression system and displayed an interlocking ring topology with a succinimide moiety as potential warhead. The activity assays of this new lanthipeptide will be carried out in the future studies. To further understand the modes of action for lanthipeptides, in Chapter 4, I investigated the mode of action of lipid II-targeting lanthipeptides. The binding event between nisin–lipid II and Halα–lipid II were characterized using isothermal titration calorimetry. Collectively, these studies further expanded our knowledge on lanthipeptides biosynthesis and discovery.","abstract_html":"Natural products and their derivatives have been significant resources for the development of therapeutic compounds. They attracted interests from both academia and industry because of their high structural diversity and potential applications. Lanthipeptides are one class of natural products that have provided antibiotics to the food industry and drug candidates for treating human diseases. Lanthipeptides are polypeptides enzymatically decorated with lanthionine rings and sometimes other post-translational modifications, which dramatically elevate their protease-resistances, improved their chemical stabilities, and increased their structural complexity. To add onto the structure knowledge and biosynthetic toolkits for lanthipeptides, I investigated the biosynthesis and discovery of lanthipeptides during my Ph.D training. Duramycin/cinnamycin-type of lanthipeptides interact tightly with phosphatidylethanolamine and several of their members displayed high potential to be drug candidates. Duramycin contains an activity-essential lysinoalanine ring which is installed by a previously unknown hypothetical protein, DurN. In Chapter 2, I described the mechanism of action studies on DurN. I reconstituted the in vitro activity of DurN. Together with Dr. Cogan, we obtained the co-crystal structures of DurN with its product or substrate analog. We demonstrated that DurN catalyzes the lysinoalanine formation through a unique substrate-assisted catalysis mechanism. Enlightened by the biosynthesis of lanthipeptide, I further designed and initiated a proof-of-concept lanthipeptide discovery project based on the predictions for the potential mode of action of natural products, which is described in Chapter 3. I hypothesized that if the gene encoding a small molecule-processing enzyme locates in the biosynthetic gene cluster of a natural product on the bacterial genome, this processing enzyme may function as the immunity protein to prevent producer viability loss during the production of the natural products, and the natural product may target the small molecule. Following this hypothesis, I identified multiple lanthipeptide biosynthesis gene cluster candidates, and selected kib cluster from Kibdelsporangium phytohabitant KLBMP 1111T for verification. The lanthipeptide was produced in heterologous expression system and displayed an interlocking ring topology with a succinimide moiety as potential warhead. The activity assays of this new lanthipeptide will be carried out in the future studies. To further understand the modes of action for lanthipeptides, in Chapter 4, I investigated the mode of action of lipid II-targeting lanthipeptides. The binding event between nisin–lipid II and Halα–lipid II were characterized using isothermal titration calorimetry. Collectively, these studies further expanded our knowledge on lanthipeptides biosynthesis and discovery.","abstract_has_math":false,"creators":["An, Linna"],"institution":"University of Illinois at Urbana-Champaign","degree_name":"Ph.D.","degree_level":"Dissertation","degree_discipline":"Chemistry","degree_department":null,"school":null,"contributors":["van der Donk, Wilfred A.","Hergenrother, Paul J.","Nair, Satish K.","Mitchell, Douglas A."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2020,"date_issued":"2020-03-02T22:15:02Z","date_published":"2020-03-02T22:15:02Z","updated_at":"2026-07-22T22:24:45Z","subjects":["lanthipeptide","biosynthesis","lipid II","duramycin","lysinoalanine","haloduracin."],"languages":["en"],"rights":["Copyright 2019 Linna An"],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/2142/106356","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["van der Donk, Wilfred A.","Hergenrother, Paul J.","Nair, Satish K.","Mitchell, Douglas A."]},{"key":"dc:creator","label":"Author","values":["An, Linna"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2020-03-02T22:15:02Z","2022-03-03T10:15:25Z","2019-11-26","2019-12"]},{"key":"dc:type","label":"Dc Type","values":["text"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Chemistry"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Ph.D."]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of Illinois at Urbana-Champaign"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["lanthipeptide","biosynthesis","lipid II","duramycin","lysinoalanine","haloduracin."]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["Copyright 2019 Linna An"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://hdl.handle.net/2142/106356"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Natural products and their derivatives have been significant resources for the development of therapeutic compounds. They attracted interests from both academia and industry because of their high structural diversity and potential applications. Lanthipeptides are one class of natural products that have provided antibiotics to the food industry and drug candidates for treating human diseases. Lanthipeptides are polypeptides enzymatically decorated with lanthionine rings and sometimes other post-translational modifications, which dramatically elevate their protease-resistances, improved their chemical stabilities, and increased their structural complexity. To add onto the structure knowledge and biosynthetic toolkits for lanthipeptides, I investigated the biosynthesis and discovery of lanthipeptides during my Ph.D training. Duramycin/cinnamycin-type of lanthipeptides interact tightly with phosphatidylethanolamine and several of their members displayed high potential to be drug candidates. Duramycin contains an activity-essential lysinoalanine ring which is installed by a previously unknown hypothetical protein, DurN. In Chapter 2, I described the mechanism of action studies on DurN. I reconstituted the in vitro activity of DurN. Together with Dr. Cogan, we obtained the co-crystal structures of DurN with its product or substrate analog. We demonstrated that DurN catalyzes the lysinoalanine formation through a unique substrate-assisted catalysis mechanism. Enlightened by the biosynthesis of lanthipeptide, I further designed and initiated a proof-of-concept lanthipeptide discovery project based on the predictions for the potential mode of action of natural products, which is described in Chapter 3. I hypothesized that if the gene encoding a small molecule-processing enzyme locates in the biosynthetic gene cluster of a natural product on the bacterial genome, this processing enzyme may function as the immunity protein to prevent producer viability loss during the production of the natural products, and the natural product may target the small molecule. Following this hypothesis, I identified multiple lanthipeptide biosynthesis gene cluster candidates, and selected kib cluster from Kibdelsporangium phytohabitant KLBMP 1111T for verification. The lanthipeptide was produced in heterologous expression system and displayed an interlocking ring topology with a succinimide moiety as potential warhead. The activity assays of this new lanthipeptide will be carried out in the future studies. To further understand the modes of action for lanthipeptides, in Chapter 4, I investigated the mode of action of lipid II-targeting lanthipeptides. The binding event between nisin–lipid II and Halα–lipid II were characterized using isothermal titration calorimetry. Collectively, these studies further expanded our knowledge on lanthipeptides biosynthesis and discovery.","Submission published under a 24 month embargo labeled 'U of I Access', the embargo will last until 2021-12-01","The student, Linna An, accepted the attached license on 2019-11-25 at 20:07.","The student, Linna An, submitted this Dissertation for approval on 2019-11-25 at 21:50.","This Dissertation was approved for publication on 2019-11-26 at 15:32.","DSpace SAF Submission Ingestion Package generated from Vireo submission #14619 on 2020-02-28 at 17:22:48","Made available in DSpace on 2020-03-02T22:15:02Z (GMT). No. of bitstreams: 5 AN-DISSERTATION-2019.pdf: 12866965 bytes, checksum: 230452a8ea15257c95f769de8e1e15d4 (MD5) Chapt_intro_lipid II biosynthesis_Rightslink? by Copyright Clearance Center_1.pdf: 57433 bytes, checksum: 26909f1cef9373f98899fd9e914c08a2 (MD5) DurN_reprint.pdf: 151098 bytes, checksum: 9243d547660f9334af8d6c51fae137fb (MD5) LICENSE.txt: 4205 bytes, checksum: a8410a523539dcc90d03d7eb85d3faa2 (MD5) PROQUEST_LICENSE.txt: 4551 bytes, checksum: 2625056e679d24314b961ae7e5ab2757 (MD5) Previous issue date: 2019-11-26","Embargo set by: Seth Robbins for item 113898 Lift date: 2022-03-02T22:15:21Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 113898 Lift date: 2022-03-02T22:18:25Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","U of I Only Restriction Lifted for Item 113898 on 2022-03-03T10:15:25Z."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["The biosynthesis and discovery of lanthipeptides"]}]}],"canonical_facts":{"dc:contributor":["van der Donk, Wilfred A.","Hergenrother, Paul J.","Nair, Satish K.","Mitchell, Douglas A."],"dc:creator":["An, Linna"],"dc:date":["2020-03-02T22:15:02Z","2022-03-03T10:15:25Z","2019-11-26","2019-12"],"dc:description":["Natural products and their derivatives have been significant resources for the development of therapeutic compounds. They attracted interests from both academia and industry because of their high structural diversity and potential applications. Lanthipeptides are one class of natural products that have provided antibiotics to the food industry and drug candidates for treating human diseases. Lanthipeptides are polypeptides enzymatically decorated with lanthionine rings and sometimes other post-translational modifications, which dramatically elevate their protease-resistances, improved their chemical stabilities, and increased their structural complexity. To add onto the structure knowledge and biosynthetic toolkits for lanthipeptides, I investigated the biosynthesis and discovery of lanthipeptides during my Ph.D training. Duramycin/cinnamycin-type of lanthipeptides interact tightly with phosphatidylethanolamine and several of their members displayed high potential to be drug candidates. Duramycin contains an activity-essential lysinoalanine ring which is installed by a previously unknown hypothetical protein, DurN. In Chapter 2, I described the mechanism of action studies on DurN. I reconstituted the in vitro activity of DurN. Together with Dr. Cogan, we obtained the co-crystal structures of DurN with its product or substrate analog. We demonstrated that DurN catalyzes the lysinoalanine formation through a unique substrate-assisted catalysis mechanism. Enlightened by the biosynthesis of lanthipeptide, I further designed and initiated a proof-of-concept lanthipeptide discovery project based on the predictions for the potential mode of action of natural products, which is described in Chapter 3. I hypothesized that if the gene encoding a small molecule-processing enzyme locates in the biosynthetic gene cluster of a natural product on the bacterial genome, this processing enzyme may function as the immunity protein to prevent producer viability loss during the production of the natural products, and the natural product may target the small molecule. Following this hypothesis, I identified multiple lanthipeptide biosynthesis gene cluster candidates, and selected kib cluster from Kibdelsporangium phytohabitant KLBMP 1111T for verification. The lanthipeptide was produced in heterologous expression system and displayed an interlocking ring topology with a succinimide moiety as potential warhead. The activity assays of this new lanthipeptide will be carried out in the future studies. To further understand the modes of action for lanthipeptides, in Chapter 4, I investigated the mode of action of lipid II-targeting lanthipeptides. The binding event between nisin–lipid II and Halα–lipid II were characterized using isothermal titration calorimetry. Collectively, these studies further expanded our knowledge on lanthipeptides biosynthesis and discovery.","Submission published under a 24 month embargo labeled 'U of I Access', the embargo will last until 2021-12-01","The student, Linna An, accepted the attached license on 2019-11-25 at 20:07.","The student, Linna An, submitted this Dissertation for approval on 2019-11-25 at 21:50.","This Dissertation was approved for publication on 2019-11-26 at 15:32.","DSpace SAF Submission Ingestion Package generated from Vireo submission #14619 on 2020-02-28 at 17:22:48","Made available in DSpace on 2020-03-02T22:15:02Z (GMT). No. of bitstreams: 5 AN-DISSERTATION-2019.pdf: 12866965 bytes, checksum: 230452a8ea15257c95f769de8e1e15d4 (MD5) Chapt_intro_lipid II biosynthesis_Rightslink? by Copyright Clearance Center_1.pdf: 57433 bytes, checksum: 26909f1cef9373f98899fd9e914c08a2 (MD5) DurN_reprint.pdf: 151098 bytes, checksum: 9243d547660f9334af8d6c51fae137fb (MD5) LICENSE.txt: 4205 bytes, checksum: a8410a523539dcc90d03d7eb85d3faa2 (MD5) PROQUEST_LICENSE.txt: 4551 bytes, checksum: 2625056e679d24314b961ae7e5ab2757 (MD5) Previous issue date: 2019-11-26","Embargo set by: Seth Robbins for item 113898 Lift date: 2022-03-02T22:15:21Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Embargo set by: Seth Robbins for item 113898 Lift date: 2022-03-02T22:18:25Z Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","U of I Only Restriction Lifted for Item 113898 on 2022-03-03T10:15:25Z."],"dc:format":["application/pdf"],"dc:identifier":["http://hdl.handle.net/2142/106356"],"dc:language":["en"],"dc:rights":["Copyright 2019 Linna An"],"dc:subject":["lanthipeptide","biosynthesis","lipid II","duramycin","lysinoalanine","haloduracin."],"dc:title":["The biosynthesis and discovery of lanthipeptides"],"dc:type":["text"],"thesis:degree_discipline":["Chemistry"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Ph.D."],"thesis:institution_name":["University of Illinois at Urbana-Champaign"]},"updated_at":"2026-07-22T22:24:45Z"}